Bioengineering news story
Researchers have uncovered critical insights into the immune dynamics of people living with HIV (PLWH) who transition from traditional daily oral therapies to the long-acting injectable regimen consisting of cabotegravir and rilpivirine.
Investigators published a comprehensive study in Scientific Reports, detailing the dynamic changes occurring in the immune profiles of PLWH undergoing this treatment switch. Their work elucidates how monocyte subsets, key players in innate immunity and inflammatory processes, adapt over time to injections of cabotegravir plus rilpivirine. Understanding these immunological recalibrations is indispensable, as chronic immune activation and inflammation in HIV are tightly linked to non-AIDS comorbidities and overall disease progression.
Read the full news story here.
